Celltrion, Inc. today announced the U.S. Food and Drug Administration (FDA) has approved a new presentation of OMLYCLO® (omalizumab-igec), the first and only biosimilar designated as interchangeable with XOLAIR® (omalizumab), in a 300mg/2mL solution in a single-dose prefilled syringe for subcutaneous injection. In the U.S., OMLYCLO will be marketed and distributed exclusively by Celltrion USA, Inc.

B.Pharm or D.Pharm from a recognized University. Must have registered with Tamil Nadu Pharmacy Council and must keep the registration alive by renewing it regularly every year.

Doctor of Philosophy in any area of Life Sciences or Biotechnology or Chemical or Computational and Information or Agricultural or Pharmaceutical or Veterinary Sciences from a recognized University.

PhD in Natural Product Chemistry / Life Sciences / Pharmaceutical Sciences / Chemistry or related disciplines. 

Masters degree in Pharmacy / Pharmaceutical Sciences / Medicine / Chemistry / Biochemistry / Physics / Biotechnology / Biomedical engineering / Natural sciences.

First class post graduate degree (M.Pharm/M.S.(Pharm)/Ph.D. Second class post graduate degree (M.Pharm/M.S.(Pharm) with Ph.D.

BSc MLT/BSc. Nursing / BPH / B.Pharma / MSW. MBBS / BDS / BAMS / BHMS with MPH OR MSc / MSW with MBA in Health Care Management & Hospital administration.

Ph.D in Pharmacy / any field of Life Sciences or equivalent degree or having 3 years of research, teaching and design and development experience after MVSc / M.Pharm / M.Tech with at least one research paper in Science Citation Indexed journal

Post graduate (Masters) degree in the relevant subject or Pharm.D (Doctor of Pharmacy) from a recognized institution.

Masters degree in Biotechnology / Biomedical engineering / Botany / Plant Biotechnology / Plant Molecular Biology / Natural sciences / Biochemistry

Proven track record of leading a large, geographically diverse sales team including experience overseeing half of India - South & West with consistent performance, growth and positive P&L outcome.

To lead Analysis work, Planning and Review. LIMS, Integration and LIMS operations. Reviewer and team handling.

Knowledge of BET, Environment Monitoring, Sterility, MLT, Culture, Media Preparation. Knowledge of injectable plant aseptic practices, Lyophilization, SVP/LVP Line etc 

Handling of medical inquiries / product quality complaints / ADR call receipt, lodging, responding and tracking of inquiries. Tracking of open inquiries and scheduling cases as needed.

Sun Pharmaceutical Industries Ltd. announced the launch of its global innovative drug, ILUMYA (Tildrakizumab) in India for moderate-to-severe plaque psoriasis. A novel biologic treatment, ILUMYA has been endorsed widely by dermatologists in the US and worldwide for several years as an effective and safe treatment of moderate to severe plaque psoriasis.

Ph.D / MD / MS / MDS or equivalent degree OR three years of research, teaching, design and development after MVSc / M.Pharm / M.E / M.Tech with at least one research paper in Science Citation Index Journal.

Masters / Integrated Masters in Natural or Agricultural or Pharmaceutical Sciences/ MVSc/ Animal Sciences. OR Bachelors degree in Engineering or Technology or Medicine from a recognized University.

Master Degree in Chemistry / Pharmaceutical Science from a recognized university / Institution. M.Sc. or B.Sc. degree with P.G. Diploma in Medical Radio Isotope Technology from BARC.

Matric or its equivalent from a recognized institution. Diploma in Allopathic Pharmacy from a recognized institution.